BioSpace News Archive

Preserves royalties payable to Minerva on worldwide sales of seltorexant Eliminates all financial obligations with respect to the clinical development and commercialization of seltorexant Corporate focus now on lead product, roluperidone, in Phase 3 development WALTHAM, Mass., July 01, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, announ

SOTIO , a clinical stage immuno-oncology company owned by PPF Group, today announced the appointment of Richard Sachse, M.D., Ph.D., as chief medical officer effective July 1, 2020. Dr. Sachse brings more than 25 years of experience in the biopharma industry as a physician and scientist and was most recently the deputy chief medical officer of SOTIO. “Dr. Sachse has professional expertise in pharmaceutical development covering

The National Institutes of Health has announced $75 million in funding to be shared by a coordinating center and a network of 10 other top academic medical centers that will launch a five-year effort to improve genomic risk assessments for diverse populations and integrate their use in clinical care.

Catalyst Biosciences, Inc. (NASDAQ: CBIO) today reported that the Compensation Committee of Catalyst’s Board of Directors granted a non-qualified inducement stock option to purchase an aggregate of 140,000 shares of Catalyst’s common stock to Clinton Musil, Catalyst’s recently appointed Chief Financial Officer, effective July 1, 2020

Microbrush, a leading US-based global manufacturer and supplier of flocked applicators, has launched a nasopharyngeal test swab to meet the growing demand for COVID-19 testing requirements.

Drug industry trade group files lawsuit against Minnesota law establishing an emergency fund to help people with diabetes access insulin when they exhaust resources

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a supplemental new drug application (sNDA) of BeiGene’s anti-PD-1 antibody tislelizumab

To Date, More Than $600 Million Committed Through Personal Protective Equipment Reimbursements, Customer Premium Relief, Provider Loans and Other Financial Assistance Initiatives to Support Providers, Members, Employees and Communities

Anivive Lifesciences, a biotechnology company focused on developing first-in-class therapies, today announced the initiation of two pre-clinical studies to further evaluate the in vivo efficacy and safety of GC376 as a treatment for COVID-19.

The U.S. Food and Drug Administration continued to take action in the ongoing response to the COVID-19 pandemic:.